Key points from article :
Biotechnology company Rubedo Life Sciences has reported promising early results from a clinical trial of an experimental skin treatment that appeared to reduce biological age markers. In a Phase 1b study involving people with atopic dermatitis, four weeks of treatment with its topical drug RLS-1496 reduced the measured epigenetic age of sun-damaged skin by an average of 2.1 years. One participant showed a reduction of 11.7 years when assessed around a month after treatment ended. The findings were presented at the Aging Research and Drug Discovery conference in Boston.
The treatment targets cellular senescence, a process in which damaged or stressed cells stop dividing but remain in the body, where they can release inflammatory signals that affect surrounding tissue. RLS-1496 acts on GPX4, a protein that helps protect cells from a form of damage that can trigger cell death. Rubedo’s approach aims to selectively eliminate harmful senescent cells while helping other stressed but viable cells activate their own protective responses. Skin samples from the trial also showed changes in ageing-related molecular markers and a 10% increase in type III collagen fibres, which help support skin structure.
Researchers also observed changes in inflammation-related proteins circulating in the blood, even though the drug was largely undetectable in patients’ circulation. This raises the possibility that treating senescent cells in one area of the body could influence inflammatory processes elsewhere. However, the reason for these changes remains unclear, and it is not yet known whether they lead to noticeable or lasting health benefits.
The results are encouraging but preliminary: the epigenetic-age analysis was based on just 11 paired skin samples, and a lower reading on an ageing clock does not necessarily mean that tissue has become functionally younger. In a separate study involving 22 people with actinic keratosis, the treatment reduced lesions by an average of 49% after 28 days. Rubedo plans to investigate the drug further, including in a study targeting hereditary hair loss. Larger, controlled trials will be needed to establish its safety, effectiveness and potential to treat conditions associated with ageing.
